Brianne Jahn
Corporate Officer/Principal at LIANBIO
Net worth: 69 397 $ as of 29/04/2024
Profile
Brianne Jahn's current job(s) include being the Chief Business Officer at LianBio and a Member-Supervisory Board at Shanghai Lianbio Development Co., Ltd.
Mr. Jahn's former job was as the Senior VP-Finance & Strategic Operations at Kadmon Holdings, Inc. from 2012 to 2020.
Mr. Jahn's education history includes an MBA from New York University and an undergraduate degree from the University of Massachusetts.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
LIANBIO
0.21% | 28/03/2023 | 224,005 ( 0.21% ) | 69 397 $ | 29/04/2024 |
Brianne Jahn active positions
Companies | Position | Start |
---|---|---|
LIANBIO | Corporate Officer/Principal | 31/08/2021 |
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Director/Board Member | - |
Former positions of Brianne Jahn
Companies | Position | End |
---|---|---|
KADMON HOLDINGS, INC. | Corporate Officer/Principal | 31/12/2019 |
Training of Brianne Jahn
University of Massachusetts | Undergraduate Degree |
New York University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
LIANBIO | Health Technology |
Private companies | 2 |
---|---|
Shanghai Lianbio Development Co., Ltd.
Shanghai Lianbio Development Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of LianBio, Shanghai Lianbio Development Co., Ltd. is a company that manufactures paradigm-shifting medicines to patients. The company is based in Shanghai, China. The CEO of the Chinese company is Debra Yu. | Health Technology |
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Brianne Jahn